From K Street to Wall Street, support for federal U.S. cannabis reform is building rapidly – setting the stage for significant changes in the investment landscape.
In this issue, we examine key considerations to keep in mind ahead of potential federal changes, including the upsides of getting in ahead of big institutions that are still on the sidelines.
Also in this issue: a closer look at leading companies in the U.S. cannabis market, signals that you shouldn’t invest in a marijuana company and how investors are responding to MedMen’s missteps.
